Metabolic, the Dubai-based metabolic health platform formerly known as GluCare.Health, said it has added Eli Lilly’s newly approved oral obesity medicine Foundayo to its treatment pathways and expects to begin offering early access in the UAE within weeks. The move comes shortly after the U.S. Food and Drug Administration approved Foundayo, orforglipron, on April 1 for adults with obesity or overweight with related medical conditions, and after the Emirates Drug Establishment cleared the drug on April 3, making the UAE the second country to register it. Metabolic said initial supplies are expected in the first week of May, placing it among the earliest providers globally to introduce the therapy and the first in its regional market, according to the company.
Why the Launch Matters
Foundayo is a once-daily, non-peptide oral GLP-1 treatment for chronic weight management, and Lilly says it can be taken at any time of day without food or water restrictions. In the ATTAIN-1 trial cited by Lilly, adults on the highest dose lost an average of 27 pounds, or 12.4% of body weight, helping position the drug as a more convenient alternative for patients who may be reluctant to use injections. Broader media coverage has focused on that practical edge, with Reuters reporting that physicians see pills as more discreet, easier to use and more appealing for patients seeking lower-burden treatment options.
Metabolic’s Care Model
Metabolic is positioning the pill not simply as another weight-loss prescription, but as a maintenance option for patients transitioning away from more intensive injectable therapies. In its announcement, the company said the oral drug would be embedded into a structured obesity program that combines medication titration with remote monitoring, biomarker tracking, behavioral support and lifestyle optimization rather than relying on prescriptions alone. The company also pointed to its 2025 outcomes data, which said 52.2% of patients in its programs achieved at least 10% weight loss after 12 months, using that record to support its argument for continuous, supervised care.
UAE Timing and Availability
The timing is notable for the UAE, where regulators have moved quickly to authorize the medicine and frame the approval as part of a broader push to speed access to innovative therapies. The Emirates Drug Establishment said the approval reflects the country’s effort to strengthen pharmaceutical innovation and improve patient experience, while local reporting said eligible patients in the Emirates are expected to gain access to the drug from May. That rollout could give providers such as Metabolic an early opening in a market where obesity remains a major health concern and where demand for needle-free treatment is likely to rise.
Market Context
Metabolic’s decision also comes as competition in the obesity-drug market accelerates, with Lilly’s Foundayo joining Novo Nordisk’s oral Wegovy in the battle for patients who may prefer pills over injections. Reuters reported that obesity specialists are already prescribing oral options to some first-time GLP-1 users because pills offer easier travel, less stigma and lower starting prices, even though injections are still viewed as more effective for severe obesity and cost remains a major barrier. On LinkedIn, obesity specialists and metabolic-health commentators described Foundayo’s approval as a breakthrough in usability and access, arguing that the simpler dosing format could improve treatment acceptance, persistence and scale in everyday practice.
Taken together, the announcement suggests Metabolic is betting that the next phase of obesity treatment will be shaped as much by convenience and continuity as by headline efficacy. By pairing a newly approved oral GLP-1 with a high-touch monitoring model, the company is attempting to distinguish itself from providers centered mainly on medication supply and short-term weight loss. Whether that strategy delivers broader uptake will become clearer once Foundayo reaches UAE patients next month, but the move already signals how quickly the oral GLP-1 market is expanding beyond the United States.